Literature DB >> 26266813

Expression of PD-L1 on CD4+CD25+Foxp3+ Regulatory T Cells of Patients with Chronic HBV Infection and Its Correlation with Clinical Parameters.

Chao Feng1, Li-Juan Cao1, Hua-Feng Song1,2,3, Ping Xu2,3, Hui Chen2,3, Jun-Chi Xu2,3, Xiao-Yan Zhu2,3, Xue-Guang Zhang1,4, Xue-Feng Wang1.   

Abstract

Regulatory T cells (Tregs) play a pivotal role in suppressing specific antiviral immune responses during the progression of chronic hepatitis B virus infection (CHB) as well as tumorigenesis. Programmed death-1 ligand-1 (PD-L1) expressed on Tregs can transduce an inhibitory signal into effector T cells through interacting with programmed death-1 (PD-1). However, in CHB patients, the clinical significance of PD-L1 expression on Tregs has not been clearly described. This study investigated the frequency of circulating Tregs and PD-L1 expression on Tregs and analyzed their correlations with clinical parameters. The data show that both the frequency of CD4+CD25+FoxP3+ Tregs and PD-L1 expression on Tregs in the peripheral blood increased significantly in CHB patients when compared with healthy controls. At the same time, it is shown that PD-L1 expression on Tregs was positively correlated with the percentage of Tregs in CHB patients. Moreover, the results demonstrated that both Treg frequency and PD-L1 expression on Tregs positively correlated with the levels of alanine aminotransaminase (ALT) and aspartate aminotransferase (AST), both of which are indicators of the extent of liver injury. Taken together, these findings suggest that PD-L1 on Tregs might contribute to progression of hepatitis B virus infection through mediating the inhibitory function of Tregs. Thereby, blockade of interaction between Treg-expressing PD-L1 and PD-1 on effector T cells may be adopted as a potential therapeutic approach in CHB.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26266813     DOI: 10.1089/vim.2015.0062

Source DB:  PubMed          Journal:  Viral Immunol        ISSN: 0882-8245            Impact factor:   2.257


  7 in total

1.  Decreased frequency of circulating Th9 cells in patients with chronic hepatitis B infection.

Authors:  Meilan Cui; Ying Lv; Jianhua Lu; Wei Zhang; Yuanyuan Duan; Yan Huang; Lei Yang; Man Li; Wenxuan Liu; Dianwu Liu; Huimin Yan
Journal:  J Clin Lab Anal       Date:  2017-05-08       Impact factor: 2.352

Review 2.  Novel Pegylated Interferon for the Treatment of Chronic Viral Hepatitis.

Authors:  Yi-Wen Huang; Albert Qin; Chan-Yen Tsai; Pei-Jer Chen
Journal:  Viruses       Date:  2022-05-25       Impact factor: 5.818

3.  Dihydroartemisinin beneficially regulates splenic immune cell heterogeneity through the SOD3-JNK-AP-1 axis.

Authors:  Yiwei Zhang; Qilong Li; Ning Jiang; Ziwei Su; Quan Yuan; Lei Lv; Xiaoyu Sang; Ran Chen; Ying Feng; Qijun Chen
Journal:  Sci China Life Sci       Date:  2022-02-23       Impact factor: 10.372

4.  Dynamic Immune Landscape and VZV-Specific T Cell Responses in Patients With Herpes Zoster and Postherpetic Neuralgia.

Authors:  Qiao Peng; Xuejiao Guo; Yang Luo; Guocan Wang; Lingyu Zhong; Jiamin Zhu; Yunze Li; Xun Zeng; Zhiying Feng
Journal:  Front Immunol       Date:  2022-06-01       Impact factor: 8.786

Review 5.  The Janus Face of Follicular T Helper Cells in Chronic Viral Infections.

Authors:  Ute Greczmiel; Annette Oxenius
Journal:  Front Immunol       Date:  2018-05-25       Impact factor: 7.561

6.  Significance of T-Cell Subsets for Clinical Response to Peginterferon Alfa-2a Therapy in HBeAg-Positive Chronic Hepatitis B Patients.

Authors:  Li Zhu; Jin Li; Junchi Xu; Fan Chen; Xunxun Wu; Chuanwu Zhu
Journal:  Int J Gen Med       Date:  2022-04-27

7.  Differential transcriptional and functional properties of regulatory T cells in HIV-infected individuals on antiretroviral therapy and long-term non-progressors.

Authors:  Shima Shahbaz; Juan Jovel; Shokrollah Elahi
Journal:  Clin Transl Immunology       Date:  2021-05-26
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.